Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

How I treat patients with massive hemorrhage

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Low vs. high hemoglobin trigger for Transfusion in Vascular surgery (TV): a randomized clinical feasibility trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A small change makes a big difference in Hodgkin lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Platelet increment is not associated with endothelial damage in haematological patients: a prospective observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Use of red blood cells in Danish intensive care units: A population-based register study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Storage time of red blood cells among ICU patients with septic shock

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Massive hemorrhage is associated with coagulopathy and high mortality. The transfusion guidelines up to 2006 recommended that resuscitation of massive hemorrhage should occur in successive steps using crystalloids, colloids and red blood cells (RBC) in the early phase, and plasma and platelets in the late phase. With the introduction of the cell-based model of hemostasis in the mid 1990ties, our understanding of the hemostatic process and of coagulopathy has improved. This has contributed to a change in resuscitation strategy and transfusion therapy of massive hemorrhage along with an acceptance of the adequacy of whole blood hemostatic tests to monitor these patients. Thus, in 2005, a strategy aiming at avoiding coagulopathy by pro-active resuscitation with blood products in a balanced ratio of RBC:plasma:platelets was introduced and this has been reported to be associated with reduced mortality in observational studies. Concurrently, whole blood viscoelastic hemostatic assays (VHA) have gained acceptance by allowing a rapid and timely identification of coagulopathy along with enabling an individualized, goal-directed transfusion therapy. These strategies joined together seem beneficial for patient outcome, although final evidence on outcome from randomized controlled trials are lacking. We here present how we in Copenhagen and Houston, today, manage patients with massive hemorrhage.

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind124
Udgave nummer20
Sider (fra-til)3052-8
ISSN0006-4971
DOI
StatusUdgivet - 7 okt. 2014

ID: 44608083